Amgen (AMGN) Gains from Investment Securities (2009 - 2026)

Amgen's Gains from Investment Securities history runs 18 years deep, the most recent figure standing at $4.0 million for Q1 2026.

• In Q1 2026, Gains from Investment Securities fell 92.0% year-over-year to $4.0 million; the TTM figure through Mar 2026 stood at -$14.0 million (down 105.83% YoY), while the FY2025 annual figure was $32.0 million, down 81.92% from the prior year.
• Gains from Investment Securities was $4.0 million for Q1 2026 at Amgen, up from -$69.0 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $355.0 million in Q4 2023 to a low of -$492.0 million in Q3 2023.
• Historically, Gains from Investment Securities has averaged -$6.5 million across 5 years, with a median of $4.0 million in 2026.
• Biggest YoY gain for Gains from Investment Securities was 1443.48% in 2023; the steepest drop was 5366.67% in 2023.
• A 5-year view of Gains from Investment Securities shows it stood at $23.0 million in 2022, then jumped by 1443.48% to $355.0 million in 2023, then decreased by 27.32% to $258.0 million in 2024, then tumbled by 126.74% to -$69.0 million in 2025, then soared by 105.8% to $4.0 million in 2026.
• The last three Gains from Investment Securities figures came in at $4.0 million (Q1 2026), -$69.0 million (Q4 2025), and $45.0 million (Q3 2025), per Business Quant data.